Novartis: 3 Key Takeaways for Long-Term Investors
Key PointsNovartis raised full-year 2026 core operating income guidance after 4% sales growth.
Three key takeaways for long-term investors from Novartis' Q3 2026 earnings call:
1. Novartis raised its full-year 2026 core operating income guidance to in-line to low-single-digit growth, up from a previously projected decline. This indicates that expanding sales of newly launched drugs are successfully replacing revenue from older medicines losing patent protection. For example, management upgraded peak sales projections for key pipeline drugs, including Rhapsido for skin conditions and remibrutinib for relapsing multiple sclerosis.
2. Operating expenses, specifically SG&A, fell 7% during the third quarter due to lower third-party spending and efficiency gains from technology. This progress is driving the company toward its target of 40% core operating margin by 2029. The company achieved a 4% growth in sales while managing SG&A costs 7% lower than the previous year.
3. Novartis' growth is driven by commercial scale across international markets and a deep pipeline of promising drugs. Management is actively tracking patent litigation outcomes and pricing discipline to maintain this growth trajectory. The long-term thesis hinges on late-stage clinical readouts, and the company remains committed to dividend growth and targeted share repurchases, supporting a dividend paid out in Swiss francs annually for nearly 30 years.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
